News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
BTG plc Reports Positive Results from First Study Investigating BGC20-0166 in Obstructive Sleep Apnoea Patients
April 10, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON & WEST CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--BTG (LSE: BGC), the life sciences company, today reports additional details from its positive clinical proof of concept study of BGC20-0166 in subjects with mild to severe obstructive sleep apnea.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase I
Europe
MORE ON THIS TOPIC
Clinical Research
Terns Climbs 10% As ‘Unprecedented’ Leukemia Data Beats Novartis’ Scemblix
December 9, 2025
·
3 min read
·
Annalee Armstrong
Obesity
Structure Stock Soars as Oral GLP-1 Generates ‘Highly Competitive’ Weight Loss
December 9, 2025
·
2 min read
·
Tristan Manalac
Infectious disease
Assembly’s Antivirals Show ‘Striking’ Drop in Lesions, Viral Shedding in Early Genital Herpes Study
December 9, 2025
·
2 min read
·
Tristan Manalac
Policy
As FDA Deploys Agentic AI, Pharma Begins Testing the Next Frontier of Intelligent Automation
December 8, 2025
·
3 min read
·
Jennifer Smith-Parker
